SCHEMBL257402

SCHEMBL257402

CCOc1ccc(-c2c(C)nn3c(-c4ccccc4)cc(=O)[nH]c23)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
PLAT P00750 5/20 0.46
MAPT P10636 6/20 0.46
MAPK1 P28482 1/20 0.46
BCL2 P10415 2/20 0.43
MDM2 Q00987 2/20 0.43
MCL1 Q07820 2/20 0.43
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
THRB P10828 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 1/20 0.42
TP53 P04637 1/20 0.42
GUSB P08236 1/20 0.41
ARF6 P62330 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257699 0.88 MAPT (0.60) NPC1RAB9APLATMAPTMAPK1
SCHEMBL15020584 0.78 PLAT (0.48) PLATMAPTMAPK1TP53ARF6
SCHEMBL15121551 0.76 TP53 (0.49) NPC1RAB9AMAPTMAPK1BCL2
SCHEMBL16556559 0.76 PLAT (0.47) PLATMAPTMAPK1ARF6TDP1
SCHEMBL10072288 0.76 MAPT (0.50) PLATMAPTMAPK1TDP1
SCHEMBL257296 0.76 PLAT (0.53) NPC1RAB9APLATALDH1A1HPGD
SCHEMBL10072102 0.75 PLAT (0.46) NPC1RAB9APLATMAPTMAPK1
SCHEMBL257514 0.75 MAPT (0.60) NPC1RAB9AMAPTMAPK1ALDH1A1
SCHEMBL256944 0.75 PLAT (0.51) NPC1RAB9APLATALDH1A1HPGD
SCHEMBL256819 0.74 PLAT (0.64) PLATMAPTMAPK1ARF6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 NPC1 114/4885RAB9A 542/4885PLAT 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.